Richard Furman, MD
Hematology · New York, NYNPI 1770670861
Payments from drug & device makers
Across 222 payments — averaging $13,965 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acerta Pharma LLC$1.9M
- TG Therapeutics, Inc.$547K
- Merck$231K
- AbbVie$92K
- Pharmacyclics LLC, An Abbvie Company$84K
- AstraZeneca$51K
- plus $205K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acerta Pharma LLC | 15 | $1,889,996 |
| TG Therapeutics, Inc. | 18 | $547,323 |
| Merck | 2 | $231,280 |
| AbbVie | 34 | $91,599 |
| Pharmacyclics LLC, An Abbvie Company | 19 | $84,331 |
| AstraZeneca | 24 | $50,640 |
| Beigene USA, Inc. | 31 | $42,596 |
| Astrazeneca UK Limited | 6 | $38,079 |
| Gilead | 5 | $35,357 |
| Incyte Corporation | 4 | $14,640 |
| Sanofi | 12 | $14,262 |
| Eli Lilly | 5 | $12,711 |
| Bristol Myers Squibb | 4 | $9,279 |
| Janssen Global Services, LLC | 7 | $9,090 |
| Beone Medicines USA, Inc. | 9 | $7,797 |
| Genentech, Inc. | 3 | $4,641 |
| Johnson & Johnson | 8 | $4,332 |
| Bioverativ Therapeutics Inc. | 1 | $3,836 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,572 |
| Beigene, Ltd. | 1 | $1,950 |
| Adaptive Biotechnologies Corporation | 6 | $1,550 |
| Ipsen Innovation | 1 | $870 |
| Janssen Scientific Affairs, LLC | 2 | $263 |
| Apellis Pharmaceuticals, Inc. | 1 | $135 |
| Genentech USA, Inc. | 2 | $104 |
| Genmab U.S., Inc. | 1 | $65 |
How this compares
$3,100,298 in reported general payments places this provider in the 95th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in New York
- Michael MauroNew York$34.9M
- Adam KittaiNew York$8.2M
- Barry CollerNew York$7.9M
- Ran ReshefNew York$5.4M
- Divaya BhutaniNew York$4.8M
- Joseph JurcicNew York$1.7M
- Marissa RybsteinNew York$1.6M
- Allyson OceanNew York$1.5M
- Mark HeaneyNew York$1.3M
- Jeffrey ZwickerNew York$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.